Unisound AI Technology Co., Ltd. (“Unisound”) reported FY2025 revenue of RMB1.21 billion, a 29.0% year-on-year rise driven by rapid commercialisation of its large-language-model (LLM) offerings. Large-model-related sales surged more than ten-fold to RMB610.00 million, accounting for roughly half of annual revenue.

Gross profit increased 19.9% to RMB437.04 million, though gross margin slipped to 36.1% (2024: 38.8%) as cost of sales climbed 34.8% to RMB774.34 million amid expanded solution deployments. Reported net loss narrowed 27.5% to RMB329.46 million, while adjusted net loss (excluding redemption-liability interest, listing expenses and asset impairment provisions) shrank 24.9% to RMB126.52 million.

By segment, Smart Life remained the main contributor with revenue of RMB967.78 million, up 30.8% and representing 79.9% of the total. Smart Healthcare delivered RMB243.60 million, a 22.3% increase, comprising 20.1% of group sales. The company’s “One Vertical, One Horizontal” strategy—combining deep domain expertise in healthcare with cross-industry AI solutions—underpinned growth.

Operating expenses totalled RMB615.46 million. R&D investment edged up 2.9% to RMB380.68 million, reaffirming focus on foundation-model and agent development. Selling and marketing costs fell 7.7% to RMB65.25 million, while administrative expenses rose 61.2% to RMB103.35 million, reflecting listing-related professional fees. Finance costs dropped 45.2% to RMB147.27 million after the derecognition of redemption-liability interest.

Liquidity strengthened: cash and cash equivalents more than doubled to RMB341.22 million, aided by HK$236.94 million in net IPO proceeds and increased bank borrowings of RMB336.50 million. The gearing ratio improved sharply to 55.6% (2024: 354.9%) following balance-sheet restructuring post-listing. Net cash outflow from operations narrowed to RMB212.78 million, while financing activities generated RMB482.97 million.

Post year-end, Unisound raised an additional HK$498.88 million net via two H-share placings completed in January and February 2026, earmarked for R&D, market expansion and working capital. The Board proposed no final dividend for 2025.